Upgrade to SI Premium - Free Trial

Mylan (MYL) and Biocon Announce FDA Approval for Ogivri to Treat HER2-Positive Breast and Gastric Cancers

December 1, 2017 11:33 AM
Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles